



Published in final edited form as:

Front Ophthalmol (Lausanne). 2022 ; 2: . doi:10.3389/fopht.2022.873486.

Effects of proinflammatory cytokines on lacrimal gland myoepithelial cells contraction

Angela Garriz^{1,*}, Junji Morokuma¹, Maytal Bowman¹, Sarah Pagni², Driss Zoukhri^{1,3}

¹Department of Comprehensive Care, Tufts University School of Dental Medicine, Boston, MA, USA

²Public Health and Community Service, Tufts University School of Dental Medicine, Boston, MA, USA

³Department of Ophthalmology, Tufts University School of Medicine, Boston, MA, USA

Abstract

In the lacrimal gland, myoepithelial cells (MEC) express muscle contractile proteins such as alpha smooth muscle actin (SMA) and calponin and therefore can contract to help expel lacrimal fluid. In a previous study, we demonstrated that lacrimal gland MEC express the oxytocin receptor (OXTR) and they contract under oxytocin (OXT) stimulation. Using NOD and MRL/lpr mice (animal models of Sjogren's syndrome), we reported a decrease in SMA and calponin protein levels plus a decline in acini contraction after stimulation with OXT. It is known that proinflammatory cytokines, such as interleukin-1 β (IL-1 β), tumor necrosis factor alpha (TNF- α) or interferon gamma (IFN- γ), can affect OXTR expression and signaling capacity and inhibit MEC contraction. The aim of the current study was to investigate if proinflammatory cytokines are implicated in the loss of MEC contractile ability. Thus, lacrimal gland MEC from a SMA-GFP transgenic mouse were treated with IL-1 β (10 ng/ml) for a total of 7 days. At days 0, 2, 4 and 7, GFP intensity, cell size/area, contractile proteins amounts and MEC contraction were assessed.

At day 0, control and treated cells showed no differences in GFP intensity and cell size. GFP intensity started to decrease in treated MEC at day 2 (20%; p=0.02), continuing after day 4 (25%; p=0.007) and 7 (30%; p=0.0001). Mean cell area was also reduced at day 2 (34%; p=0.0005), and after 4 (51%; p<0.0001) and 7 days (30%; p=0.0015). The contraction assay at day 2 showed a 70% decrease of contraction in treated MEC (p<0.0001), 73% (p<0.0001) at day 4 and 82% (p=0.0015) at day 7 when compared to control. Levels of contractile proteins were measured on day 7 showing a decrease in SMA and calponin amount in treated MEC compared with the control group (around 30%; p=0.0016 and p=0.0206; respectively). Similar results were observed when TNF- α and IFN- γ were added along with IL-1 β .

Taken together the present data and those from our previous studies with Sjogren's syndrome mouse models, they strongly suggest that proinflammatory cytokines affect lacrimal gland MEC

*Corresponding Author: angela.garriz@tufts.edu.

SUPPLEMENTARY MATERIAL

Total protein staining from lacrimal gland MEC lysates used to quantify SMA and calponin protein levels in the western blotting data showed in Figure 3.

contractile ability that may account for the reduced tear secretion associated with Sjogren's syndrome dry eye disease.

Keywords

Contractile proteins; Interleukin-1 β ; Inflammation; Myoepithelial cells; Lacrimal gland

INTRODUCTION

Lacrimal gland myoepithelial cells (MEC) form an extensively branched network surrounding the acinar and ductal cells of the lacrimal gland epithelium, being an important component of its secretory apparatus (1-3). MEC are able to contract helping to expel lacrimal fluid and they express muscle contractile proteins such as alpha smooth muscle actin (SMA) and calponin as well as epithelial markers (keratin 5 and 14) (3). They also express both muscarinic and purinergic receptors implying that MEC can respond to neural stimuli (4-6).

We have recently demonstrated that lacrimal gland MEC express the oxytocin receptor (OXTR) and they contract under oxytocin (OXT) stimulation (7, 8). The OXTR, like many other G protein coupled receptors (GPCRs), can be desensitized by prolonged agonist stimulation which can lead to a reduced signal transduction (9-11). Normal desensitization of GPCRs is commonly mediated through β -arrestin binding, however, under inflammatory conditions, OXTR down-regulation has also been observed (12, 13).

Proinflammatory cytokines, such as interleukin-1beta (IL-1 β), tumor necrosis factor alpha (TNF- α) or interferon gamma (IFN- γ), have been shown to be key mediator in lacrimal gland inflammation associated with Sjogren's syndrome affecting OXTR expression and signaling capacity and impair MEC contraction critically impeding lacrimal gland fluid release (14). In addition, it has been reported that IL-1 β decreases OXTR mRNA levels and downregulates OXT binding capacity in myometrial and decidua human cell cultures (15-18).

In our previous study, using animal models of Sjogren's syndrome (NOD and MRL/lpr mice), we reported a decrease in SMA and calponin protein levels plus a decline in acini contraction after stimulation with OXT (7). These results indicated that MEC function is impaired during chronic inflammation of the lacrimal gland. Thus, the aim of the current study was to investigate if proinflammatory cytokines are implicated in the loss of MEC contractile ability. Lacrimal gland MEC from a GFP-SMA transgenic mouse strain were treated with IL-1 β (10 ng/ml) for a total of 7 days. At day 0, 2, 4 and 7, GFP intensity, cell area, contractile proteins amounts and MEC contraction were assessed. Our data show that chronic treatment with proinflammatory cytokines decreased GFP intensity, cell size, SMA and calponin protein expression and inhibited OXT-induced MEC contraction. Similar results were observed when TNF- α and IFN- γ were added along with IL-1 β .

MATERIALS AND METHODS

Cytokines, chemicals, and antibodies.

Recombinant human IL-1 β , recombinant human TNF- α and recombinant human IFN- γ were purchased from PEPROTECH (Rocky Hill, NJ). Oxytocin was purchased from Sigma-Aldrich (Saint Louis, MO). Cell media Dulbecco's Modified Eagle (DMEM) and RPMI-1640 medium (Roswell Park Memorial Institute), collagenase type II, penicillin-streptomycin, L-glutamine, and fetal bovine serum (FBS) were from Gibco (Waltham, MA). TrypLE Express was from Invitrogen (Carlsbad, CA). Rabbit polyclonal antibody against α SMA (ab5694 at 1:400 dilution) and rabbit monoclonal antibody against calponin (ab46794 at 1:2000 dilution) were from Abcam (Waltham, MA). All secondary antibodies were from LI-COR (Lincoln, NE).

Animals.

All experiments described herein were performed in accordance with the Association for Research in Vision and Ophthalmology (ARVO) statement for the use of animals in ophthalmic and vision research and were approved by the Tufts Medical Center Institutional Animal Care and Use Committee. Mice were maintained in constant temperature rooms with fixed light/dark intervals of 12 h length and were fed ad libitum. To obtain MEC, α SMA-GFP mice (C57BL6) / *SMA^{CreErt2}* strain was used for this study that was described by Yokota (19) and were a kind gift of Dr. Ivo Kalajzic (UConn Health, Farmington, CT). In these mice, the lacrimal gland MEC, which express SMA, are therefore labeled with GFP.

Isolation and propagation of lacrimal gland MEC.

Four- to 6-week-old SMA-GFP mice were euthanized and the exorbital lacrimal glands were removed and minced into lobules for collagenase digestion using our previously described protocol (5, 8). Briefly, lacrimal glands were washed in cold DMEM, gently minced with a scalpel and forceps to prepare 2-3 mm lobules and placed in digestion media (1.5 mL/gland of DMEM and 1.65 mg/mL of collagenase type II). Samples were then incubated in a shaking water bath (37°C and 100 rpm) for 20-30 minutes. At regular 5 min intervals, lobules were gently pipetted, 10 times, through tips of decreasing diameter. Digested media was filtered through a sterile cell strainer (100 μ m nylon mesh; Thermo Fisher Scientific, Waltham, MA), remaining tissue pushed through the mesh using the pipette tip, and collected cells washed with 1-2 mL DMEM. Cells were then centrifuged at 100 x *g* for 5 minutes, resuspended in complete RPMI-1640 medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine, and 100 μ g/mL penicillin-streptomycin and centrifuged again at 100 x *g* for 5 minutes. Pelleted cells were resuspended in 10 mL complete RPMI media, plated in 100 mm culture dishes (VWR, Radnor, PA) and placed in a 37°C incubator (5% CO₂).

Cytokine treatment of lacrimal gland MEC.

Lacrimal gland MEC were seeded in 6-well plates in 5% FBS RPMI Media. Confluent to sub-confluent MEC cultures were treated with 10 ng/ml of IL-1 β alone or in combination with 10 ng/ml each of TNF- α and IFN- γ , for a total of 7 days. Every other day media was

changed, and 4-5 pictures were randomly taken from each well to perform further analysis of GFP intensity and cell area measurements. In other experiments, cells were trypsinized to perform the contraction assay, as described below. After the last day of treatment (day 7), cells were lysed, and protein samples were prepared for western blotting studies, as described below.

Image analysis of GFP intensity and cell size measurements.

Images of MEC cultures were taken on day 0 (before addition of cytokines) then 2, 4 and 7 days of cytokines treatment using a digital camera (SPOT Insight CMOS; SPOT Imaging, Sterling Heights, MI) mounted on an inverted light microscope (Eclipse TE2000-S; Nikon Instruments Inc., Melville, NY). Total GFP intensity was analyzed, in each of these time frames from control and treated MEC, using ImageJ/Fiji software (ImageJ 1.53, National Institutes of Health, USA). Analyzing GFP intensity is an indirect indicator of SMA protein levels since GFP expression in MEC is under the control of the SMA promoter. In addition, a minimum of 5 to 6 cells per photograph were selected to measure the cell area (μm^2) using SPOT Advanced Imaging software (Version 5.6).

SDS-PAGE and Western Blotting.

At the end of the cytokine treatment, lacrimal gland MEC from treated and control groups were lysed in 0.2 mL ice-cold radio-immunoprecipitation assay (RIPA) buffer (10 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, and 0.1% SDS supplemented with protease inhibitors). Cell lysates were centrifuged at $20,000 \times g$ for 30 minutes and the supernatant collected. Proteins were separated by SDS-PAGE on NuPage 4–12% Bis-Tris gels in MOPS-SDS buffer (Invitrogen, Carlsbad, CA). Protein in the gels were transferred to nitrocellulose membranes using NuPage transfer buffer (Invitrogen) and processed for immunoblotting. After transfer, nitrocellulose membranes were stained with REVERT Total Protein Stain (LI-COR) following the manufacturer's instructions and prior to being blocked using Odyssey blocking buffer (LI-COR) for 1 hour at room temperature. Membranes were then incubated overnight at 4°C with the appropriate primary antibody for SMA and calponin diluted in blocking buffer + 0.1% tween-20. Following washing with Tris-buffered saline + tween-20 (TBS; 50 mM Tris-HCl, 150 mM NaCl, 0.1% tween-20, pH 7.6) membranes were then incubated for 1 hour at room temperature with their appropriate secondary antibodies followed by detection on a LI-COR Odyssey Infrared Imager. Staining in each lane for REVERT total protein stain (see supplementary material), and band intensity for immunoblotting was quantified using the LI-COR Image Studio software (v.4.0). Western blot band quantifications were then normalized to the total amount of protein in each lane.

MEC contraction assay.

On days 2, 4 or 7, cells were trypsinized from the 6-well plate and seeded overnight in a 24-well-plate, at a density of around 5,000 cells/well. Cells treated with cytokines and untreated cells (control) were stimulated with OXT (10^{-6} M) for 20 minutes. Video recording of the contraction process was performed using a digital camera (SPOT Insight CMOS; SPOT Imaging, Sterling Heights, MI) mounted on an inverted fluorescence microscope (Eclipse TE2000-S; Nikon Instruments Inc., Melville, NY). Also, still images were taken before and

20 min after OXT stimulation for image analyses. At least 10 random cells from each well and each condition were used for image analyses, using ImageJ/Fiji software (ImageJ 1.53, National Institutes of Health, USA). The perimeter of the same cell was calculated before and after OXT stimulation, and the difference between these two values that represents the decrease in cell size after OXT stimulation, was expressed in percentage.

Statistical analyses and data presentation.

Statistical analyses were performed using GraphPad Prism Software (version 9.0; San Diego, CA). Where appropriate, data are presented as means \pm standard deviation (SD). Data consisting of 2 groups were analyzed using a 2-tailed unpaired Student's *t*-test or the Mann-Whitney U test for non-normally distributed data with significant results being considered at p -value < 0.05 .

RESULTS

Effect of IL-1 β on GFP intensity and MEC size.

Since GFP expression in the transgenic mouse used in our studies is under the control of the SMA promoter, a decrease in GFP intensity would imply a decrease in SMA expression. Lacrimal gland MEC were left untreated or incubated with IL-1 β for up to 7 days. Images were taken at days 0, 2, 4, and 7 and used for image analyses to quantify GFP intensity or MEC size, as described in the Methods section. As shown in Figure 1, at day 0, control and treated cells showed no difference in GFP intensity. GFP intensity started to decrease in treated MEC at day 2 (20%; $p=0.02$), continuing at day 4 (25%; $p=0.007$) and day 7 (30%; $p=0.0001$) (Fig. 1).

The data in Figure 2 summarizes the effect of IL-1 β treatment on MEC size. At day 0 there was no significant difference in cell size between the treated and control group. However, mean cell area was reduced at day 2 (34%; $p=0.0005$), day 4 (51%; $p<0.0001$) and day 7 (30%; $p=0.0015$) in treated MEC treated compared with the control group (Fig. 2).

These data suggest that chronic treatment of lacrimal gland MEC with IL-1 β lead to degradation of SMA protein, which resulted in smaller sized cells. Quantification of SMA and calponin protein expression levels, as discussed below, lend support to this hypothesis.

Effect of IL-1 β treatment on MEC contractile proteins levels.

The data from the GFP intensity analyses suggested that chronic treatment of lacrimal gland MEC with IL-1 β lead to lower expression of SMA protein. To test this hypothesis, we prepared cell lysates from control and IL-1 β treated MEC and performed western blotting analyses to quantify the level of expression of SMA as well as calponin. As shown in Figure 3, there was a 33% decrease in the amount of SMA and calponin protein in treated MEC compared with the control group ($p=0.0016$ and $p=0.0206$, respectively). Please note that, as expected, SMA expression decreased to a similar level as did GFP intensity (Fig. 1).

These data suggest that chronic treatment of MEC with IL-1 β lead to lower expression of SMA and calponin proteins.

Effect of IL-1 β on OXT-induced MEC contraction.

So far, our data suggest that chronic IL-1 β treatment led to degradation of contractile proteins which could result in impaired lacrimal gland MEC contraction. Cells incubated with IL-1 β for 2, 4 or 7 days were trypsinized, seeded overnight on 24-well plates to perform contraction assay as described in the Methods section. As shown in Figure 4, compared to controls, day 2 treated MEC showed a 70% ($p < 0.0001$) decrease in OXT-induced contraction. Contraction was further decreased by 73% ($p < 0.0001$) at day 4 and 82% ($p = 0.0015$) at day 7 (Fig. 4).

These data suggest that IL-1 β induced lower expression of SMA and calponin proteins led to inhibition of OXT-induced MEC contraction.

Effects of IL-1 β , TNF- α and IFN- γ , on GFP intensity, cell size and contractile protein expression.

The proinflammatory cytokines TNF- α and IFN- γ , are known to be elevated in chronically inflamed lacrimal glands as occurs in Sjogren's syndrome. Therefore, we tested their effect, when added with IL-1 β , on MEC functions. At day 0, GFP intensity and cell size of treated and untreated MEC was not significantly different (data non shown). In contrast, both GFP intensity and MEC size were significantly decreased following treatment with the cytokine cocktail for 7 days (Fig. 5A and B). When compared to IL-1 β alone, the cytokine cocktail decreased GFP intensity and cell size to a larger extent: 57% vs. 30% and 41% vs. 30%; respectively (Fig. 1, 2, and 5). Similarly, the amounts of the contractile proteins, SMA and calponin, were also decreased, although not statistically significantly, following cytokine cocktail treatment (Fig. 5C).

These data suggest that TNF- α and IFN- γ can synergize with IL-1 β to further impact MEC functions in chronically inflamed lacrimal glands.

DISCUSSION

The data from the current studies show that chronic treatment of lacrimal gland MEC with the proinflammatory cytokine IL-1 β led to lower expression of the contractile proteins, SMA and calponin, which resulted in smaller sized cells and inhibition of OXT-induced MEC contraction. These *in vitro* findings recapitulate our previously published *in vivo* findings in animal models of Sjogren's syndrome with chronically inflamed lacrimal glands (7). Namely, the lower expression of SMA and calponin proteins, the reduced MEC size, and the loss of OXT-induced contraction.

It is known that several proinflammatory cytokines are highly expressed in Sjogren's syndrome target organs (20-22). Some of the pro-inflammatory cytokines thought to play an important role in Sjogren's syndrome pathophysiology are the interferons (IFN), IL-12, IL-18, TNF- α , IL-1 β , IL-6 and B-cell activating factor (BAFF) (21). These cytokines are highly expressed in Sjogren's syndrome with IFN in particular being responsible for activation of autoreactive T and B cells in the lacrimal glands (21, 23). In the current studies, addition of two other proinflammatory cytokines known to be associated with Sjogren's

syndrome pathophysiology, TNF- α and IFN- γ , seemed to potentiate (or synergize) the effects of IL-1 β .

The mechanisms involved in proinflammatory cytokine-induced degradation of MEC contractile proteins and inhibition of OXT-induced contraction remain to be investigated. In several muscle tissues, studies have shown that both the OXTR as well as contractile proteins are down regulated by proinflammatory cytokines. For example, studies showed that proinflammatory cytokines, especially IL-1 β , down-regulate the expression of the OXTR in uterine smooth muscle (15, 17). The effect of IL-1 β was both at the mRNA level as well as the OXTR protein level, although the molecular mechanisms were not described (17). A study by Castro *et al.* (24) reported that matrix metalloproteinase 2 (MMP-2) interacts with calponin-1 in aortic vascular smooth muscle cells and that MMP-2 mediated proteolysis of calponin-1 during endotoxemia contributes to LPS-induced hypocontractility. It is worth noting that we showed that inhibition of MMP-2 leads to increased tear production in an animal model of Sjogren's syndrome dry eye disease (25). Future studies testing the effect of MMP-2 inhibition on proinflammatory cytokine induced lacrimal gland MEC dysfunction are needed.

In myometrial cells, the activation of the transcriptional regulatory nuclear factor κ B (NF- κ B) family is the main component in IL-1 β signaling cascade (26-28). Several studies showed a concerted increase in the expression of genes of the ubiquitin/proteasome pathway, including the muscle specific ubiquitin ligases Trim63 (MuRF-1), Fbxo32 (Atrogin-1), as well as many other 20S and 19S proteasome subunits and cathepsin L, activating as a final protein breakdown the ubiquitin pathway (29). In several disease conditions, calpain and/or caspase-3 were reported to mediate this initial breakdown (30-32). The role of these pathways in proinflammatory cytokine-mediated lacrimal gland MEC dysfunction remain to be investigated.

In conclusion, our data show that chronic treatment of lacrimal gland MEC with the proinflammatory cytokine IL-1 β lead to lower expression of the contractile proteins SMA and calponin, reduced cell size and a profound inhibition of OXT-induced contraction. The addition of two other proinflammatory cytokines, TNF- α and IFN- γ , seemed to potentiate the effect of IL-1 β on lacrimal gland MEC. These *in vitro* findings coupled with our published *in vivo* findings suggest that targeting proinflammatory cytokine in chronically inflamed lacrimal gland is a potential therapeutic target to restore MEC contractile ability and tear secretion in dry eye disease.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGEMENTS

The authors would like to thank Marie-Zoe Schnellmann for her help with the MEC contraction assays and Ivo Kalajzic (UConn Health, Farmington, CT, USA) for the generous gift of SMA-GFP mice.

Supported by NIH R01EY029870.

REFERENCES

1. Wang YL, Tan Y, Satoh Y, Ono K. Morphological changes of myoepithelial cells of mouse lacrimal glands during postnatal development. *Histol Histopathol.* 1995;10(4):821–7. [PubMed: 8574002]
2. Leeson TS, Leeson CR. Myoepithelial cells in the exorbital lacrimal and parotid glands of the rat in frozen-etched replicas. *The American journal of anatomy.* 1971;132(2):133–45. [PubMed: 5112466]
3. Makarenkova HP, Dartt DA. Myoepithelial Cells: Their Origin and Function in Lacrimal Gland Morphogenesis, Homeostasis, and Repair. *Curr Mol Biol Rep.* 2015;1(3):115–23. [PubMed: 26688786]
4. Lemullois M, Rossignol B, Mauduit P. Immunolocalization of myoepithelial cells in isolated acini of rat exorbital lacrimal gland: cellular distribution of muscarinic receptors. *Biol Cell.* 1996;86(2-3):175–81. [PubMed: 8893507]
5. Ohtomo K, Shatos MA, Vrouvianis J, Li D, Hodges RR, Dartt DA. Increase of intracellular Ca²⁺ by purinergic receptors in cultured rat lacrimal gland myoepithelial cells. *Invest Ophthalmol Vis Sci.* 2011;52(13):9503–15. [PubMed: 22039237]
6. Emmelin N, Garrett JR, Ohlin P. Neural control of salivary myoepithelial cells. *J Physiol.* 1968;196(2):381–96. [PubMed: 5652882]
7. Hawley D, Tang X, Zyrianova T, Shah M, Janga S, Letourneau A, et al. Myoepithelial cell-driven acini contraction in response to oxytocin receptor stimulation is impaired in lacrimal glands of Sjogren's syndrome animal models. *Sci Rep.* 2018;8(1):9919. [PubMed: 29967327]
8. Garriz A, Aubry S, Wattiaux Q, Bair J, Mariano M, Hatzipetrou G, et al. Role of the Phospholipase C Pathway and Calcium Mobilization in Oxytocin-Induced Contraction of Lacrimal Gland Myoepithelial Cells. *Invest Ophthalmol Vis Sci.* 2021;62(14):25.
9. Jasper JR, Harrell CM, O'Brien JA, Pettibone DJ. Characterization of the human oxytocin receptor stably expressed in 293 human embryonic kidney cells. *Life Sci.* 1995;57(24):2253–61. [PubMed: 7475979]
10. Phaneuf S, Asboth G, Carrasco MP, Europe-Finner GN, Saji F, Kimura T, et al. The desensitization of oxytocin receptors in human myometrial cells is accompanied by down-regulation of oxytocin receptor messenger RNA. *J Endocrinol.* 1997;154(1):7–18. [PubMed: 9246933]
11. Phaneuf S, Asboth G, MacKenzie IZ, Melin P, Lopez Bernal A. Effect of oxytocin antagonists on the activation of human myometrium in vitro: atosiban prevents oxytocin-induced desensitization. *Am J Obstet Gynecol.* 1994;171(6):1627–34. [PubMed: 7802080]
12. Lohse MJ, Benovic JL, Codina J, Caron MG, Lefkowitz RJ. beta-Arrestin: a protein that regulates beta-adrenergic receptor function. *Science.* 1990;248(4962):1547–50. [PubMed: 2163110]
13. Rockman HA, Koch WJ, Lefkowitz RJ. Seven-transmembrane-spanning receptors and heart function. *Nature.* 2002;415(6868):206–12. [PubMed: 11805844]
14. Zoukhri D, Hodges RR, Byon D, Kublin CL. Role of proinflammatory cytokines in the impaired lacrimation associated with autoimmune xerophthalmia. *Invest Ophthalmol Vis Sci.* 2002;43(5):1429–36. [PubMed: 11980857]
15. Friebe-Hoffmann U, Baston DM, Hoffmann TK, Chiao JP, Rauk PN. The influence of interleukin-1beta on oxytocin signalling in primary cells of human decidua. *Regul Pept.* 2007;142(3):78–85. [PubMed: 17428554]
16. Helmer H, Tretzmuller U, Brunbauer M, Kaider A, Husslein P, Knofler M. Production of oxytocin receptor and cytokines in primary uterine smooth muscle cells cultivated under inflammatory conditions. *J Soc Gynecol Investig.* 2002;9(1):15–21.
17. Rauk PN, Friebe-Hoffmann U. Interleukin-1 beta down-regulates the oxytocin receptor in cultured uterine smooth muscle cells. *Am J Reprod Immunol.* 2000;43(2):85–91. [PubMed: 10735599]
18. Schmid B, Wong S, Mitchell BF. Transcriptional regulation of oxytocin receptor by interleukin-1beta and interleukin-6. *Endocrinology.* 2001;142(4):1380–5. [PubMed: 11250916]
19. Yokota T, Kawakami Y, Nagai Y, Ma JX, Tsai JY, Kincade PW, et al. Bone marrow lacks a transplantable progenitor for smooth muscle type alpha-actin-expressing cells. *Stem Cells.* 2006;24(1):13–22. [PubMed: 16099999]
20. Roescher N, Tak PP, Illei GG. Cytokines in Sjogren's syndrome. *Oral Dis.* 2009;15(8):519–26. [PubMed: 19519622]

21. Youinou P, Pers JO. Disturbance of cytokine networks in Sjogren's syndrome. *Arthritis Res Ther*. 2011;13(4):227. [PubMed: 21745420]
22. Ogawa Y, Shimizu E, Tsubota K. Interferons and Dry Eye in Sjogren's Syndrome. *Int J Mol Sci*. 2018;19(11).
23. Nocturne G, Mariette X. B cells in the pathogenesis of primary Sjogren syndrome. *Nat Rev Rheumatol*. 2018;14(3):133–45. [PubMed: 29416129]
24. Castro MM, Cena J, Cho WJ, Walsh MP, Schulz R. Matrix metalloproteinase-2 proteolysis of calponin-1 contributes to vascular hypocontractility in endotoxemic rats. *Arterioscler Thromb Vasc Biol*. 2012;32(3):662–8. [PubMed: 22199370]
25. Aluri HS, Kublin CL, Thotakura S, Armaos H, Samizadeh M, Hawley D, et al. Role of Matrix Metalloproteinases 2 and 9 in Lacrimal Gland Disease in Animal Models of Sjogren's Syndrome. *Invest Ophthalmol Vis Sci*. 2015;56(9):5218–28. [PubMed: 26244298]
26. O'Neill LA. Towards an understanding of the signal transduction pathways for interleukin 1. *Biochim Biophys Acta*. 1995;1266(1):31–44. [PubMed: 7718619]
27. Belt AR, Baldassare JJ, Molnar M, Romero R, Hertelendy F. The nuclear transcription factor NF-kappaB mediates interleukin-1beta-induced expression of cyclooxygenase-2 in human myometrial cells. *Am J Obstet Gynecol*. 1999;181(2):359–66. [PubMed: 10454683]
28. Soloff MS, Izban MG, Cook DL Jr., Jeng YJ, Mifflin RC. Interleukin-1-induced NF-kappaB recruitment to the oxytocin receptor gene inhibits RNA polymerase II-promoter interactions in cultured human myometrial cells. *Mol Hum Reprod*. 2006;12(10):619–24. [PubMed: 16888077]
29. Lecker SH, Jagoe RT, Gilbert A, Gomes M, Baracos V, Bailey J, et al. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. *FASEB J*. 2004;18(1):39–51. [PubMed: 14718385]
30. Du J, Wang X, Miereles C, Bailey JL, Debigare R, Zheng B, et al. Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions. *J Clin Invest*. 2004;113(1):115–23. [PubMed: 14702115]
31. Lecker SH, Goldberg AL, Mitch WE. Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. *J Am Soc Nephrol*. 2006;17(7):1807–19. [PubMed: 16738015]
32. Wei W, Fareed MU, Evenson A, Menconi MJ, Yang H, Petkova V, et al. Sepsis stimulates calpain activity in skeletal muscle by decreasing calpastatin activity but does not activate caspase-3. *Am J Physiol Regul Integr Comp Physiol*. 2005;288(3):R580–90. [PubMed: 15563579]




Figure 1. Effect of IL-1 β on GFP intensity.

Lacrimal gland MEC were either left untreated (control) or incubated with IL-1 β (10 ng/ml) for 2, 4, or 7 days. Three or 4 random images were taken, using the same camera setting for all conditions, from each well and GFP intensity was quantified using ImageJ/Fiji software, as described in the Methods section. (A) Shows representative images from control and treated MEC at all time points measured and (B) Shows averaged data from 4 independent experiments. Compared to the control group, IL-1 β treatment significantly decreased GFP intensity at all time points measured (Mann-Whitney U test). Data are means \pm SD; n=20-23 for day 0; n=32 for day 2; n=31-32 for day 4; and n=28 for day 7 with all data from 4 independent experiments. Scale bar = 50 μ m.




Figure 2. Effect of IL-1 β on MEC size.

Lacrimal gland MEC were either left untreated (control) or incubated with IL-1 β (10 ng/ml) for 2, 4, or 7 days. Three or 4 random images were taken, using the same camera setting for all conditions, from each well MEC size was quantified using SPOT Imaging software, as described in the Methods section. (A) Shows representative images from control and treated MEC at all time points measured and (B) Shows averaged data from 4 independent experiments. Compared to the control group, IL-1 β treatment significantly decreased MEC size at all time points measured (Student's *t*-test). Data are means \pm SD; $n=23-24$ for day 0; $n=19$ for day 2; $n=15-16$ for day 4; and $n=27-28$ for day 7 with all data from 4 independent experiments. Scale bar = 50 μm .




Figure 3. Effect of IL-1 β on SMA and calponin protein levels.

Lacrimal gland MEC were either left untreated (control) or treated with IL-1 β (10 ng/ml) for 7 days. SMA and calponin protein level were quantified by western blotting and reported as a ratio relative to total protein stain, as described in the Methods section. (A) Shows western blots for SMA (top) and calponin (bottom) in control (C) and IL-1 β treated (T) MEC samples. (B) Graphs showing the amount of SMA and calponin in control and treated lacrimal gland MEC relative to total protein stain. SMA and calponin amounts are significantly decreased in lacrimal gland MEC treated with IL-1 β compared with the control ($P=0.0016$ and $P=0.0206$; respectively, Student's *t*-test.). Data in the plots are means \pm SD, $n=7$ from 4 independent experiments.




Figure 4. Effect of IL-1 β on oxytocin-induced lacrimal gland MEC contraction.

Lacrimal gland MEC were either left untreated (control) or incubated with IL-1 β (10 ng/ml) for 2, 4, or 7 days. Cells were trypsinized for each time period, reseeded at low density and then stimulated with OXT (10^{-6} M) for 20 minutes. Changes in MEC size (i.e., contraction) following OXT stimulation was measured using ImageJ/Fiji software, as described in the Methods section. Chronic treatment of MEC with IL-1 β significantly inhibited OXT-induced contraction at all three time points (Student's *t*-test). Data are means \pm SD; $n=30-35$ for day 2; $n=28-29$ for day 4 and $n=34-35$ for day 7 with all data from 3 independent experiments.




Figure 5. Effect of a cytokine cocktail on GFP intensity, MEC size and contractile protein expression.

Lacrimal gland myoepithelial cells were treated for 7 days with 3 cytokines, IL-1 β , TNF- α and IFN- γ , 10 ng/ml each. **(A)** Representative images of MEC at day 7 following cytokine treatment showing a decrease in GFP intensity. Scale bar = 50 μm . The graph next to the images shows a statistically significant decrease in GFP intensity in treated MEC compared with the control ($P = 0.002$; Mann-Whitney U test). Data are means \pm SD, $n=15-16$ from 4 repeated experiments. **(B)** Representative images of MEC area measurements at day 7 following cytokine treatment showing a decrease in cell size. Scale bar = 50 μm . The graph next to the images shows a statistically significant decrease of MEC size in cytokine treated compared with the control ($P < 0.001$; Student's t -test; data are means \pm SD, $n=13-14$ from 4 independent experiments). **(C)** Graphs showing the amount of alpha smooth muscle actin (SMA) and calponin from MEC lysates treated with cytokines for 7 days compared with the control. The amount of both proteins tends to decrease, although not statistically significant (Mann-Whitney U test), in MEC treated with cytokines compared with the control. Data are means \pm SD, $n = 4$.